Ciliatocholate (Ciliatocholic acid) is a nucleoside metabolite.

CI-996 is a potent, selective, orally active angiotensin II (Ang II) type 1 (AT1) receptor antagonist. In rat liver membranes CI-996 displaces specifically bind [125I]Ang II with an IC50 of 0.8 nM. CI-996 has blood pressure-lowering activity.

CI-986 is a dual inhibitor of COX and 5-LOX. CI-986 can prevent the coronary vasoconstriction and the increased production of LTB(4) and LTC(4). CI-986 also has anti-inflammatory and analgesic effects. CI-986 can be used for the researches of inflammation and cardiovascular disease, such as arthritis.

CI-959 is an inhibitor of inflammatory cell activation. CI-959 exhibits anti-inflammatory and anti-allergic activities. CI-959 can inhibit the production of reactive oxygen species by neutrophils, as well as neutrophil adhesion, respiratory burst, and histamine release from mast cells. CI-959 can also inhibit the release of inflammatory mediators such as histamine, leukotrienes, and thromboxane from guinea-pig and human lung tissues, and effectively suppress anti-IgE-induced contractions of human bronchial smooth muscle. CI-959 can be used in the research of inflammatory and allergic diseases, such as asthma.

CHX-3107 is a casein kinase 2 inhibitor .

CHNQD-03301 is an orally active hypoxia-inducible factor-1α (HIF-1α) inhibitor (IC50 = 10.97 nM). CHNQD-03301 promotes the proteasomal degradation of HIF-1α protein, leading to its significant suppression. CHNQD-03301 can reverse HIF accumulation-induced angiogenesis and mitigate the HIF-induced erythrocytosis phenotype in zebrafish models. CHNQD-03301 can be used for the study of colon cancer.

Chlorproethazine hydrochloride is an orally active phenothiazine compound. Chlorproethazine hydrochloride can eliminate spasticity when administered intravenously and also effectively reduce rigidity in decerebrate cats. Chlorproethazine hydrochloride can be used in the research of neurological diseases.

Chenodeoxycholyl-putrescine is a polyamine bile amidate.

CGP 47645 is a long-acting nonsteroidal aromatase inhibitor. CGP 47645 can significantly affect testicular function. CGP 47645 can be used to study the physiological role of estrogen in regulating testicular function.

cGAS-IN-6 (14) is a cGAS inhibitor. cGAS-IN-6’s core structure is a fused imidazole ring system. cGAS-IN-6 can be used for research on autoimmune conditions.

CDK7-IN-33 (formula Ⅰ) is a pyrimidine derivative and also a CDK7 kinase inhibitor. CDK7-IN-33 is applicable to the research of cancer, inflammation, cardiovascular diseases, infectious diseases, immune diseases and metabolic diseases.

CDK4-IN-4 (example 30) is a selective CDK4 inhibitor (IC50＜10 nM) that can be used in cancer research.

CDK2-IN-55 (Compound 12c) is a CDK2 inhibitor with an IC50 value of 4.7 nM. CDK2-IN-55 also has a strong inhibitory effect on CDK1 (IC50 = 26.3 nM), moderate inhibitory effects on Aurora A (IC50 = 92.0 nM) and CDK9 (IC50 = 288 nM), and very weak inhibitory activities on CDK4, CDK6, DYRK1A, and GSK3β (IC50 > 1000 nM). CDK2-IN-55 shows strong anti-proliferative activity against various cancer cell lines, inducing cell cycle arrest and apoptosis. CDK2-IN-55 can be used for research on colorectal cancer, lung cancer, and cervical cancer.

CDK2-IN-54 (Formula I) is a CDK2 inhibitor. CDK2-IN-54 can be used in cancer research such as triple-negative breast cancer, ovarian cancer, bladder cancer, and uterine cancer.

CDK2-IN-52 (Compound Cpb No 39) is a selective cyclin-dependent kinase 2 (CDK2) inhibitor with a DC50 value of 1-10 nM. CDK2-IN-52 induces cell cycle arrest and suppresses tumor cell proliferation. CDK2-IN-52 is promising for research of CDK2-overexpressing malignancies such as breast and ovarian cancers.

CDK12 ligand-3 is a molecular glucose degrading agent that targets the CDK12 protein (DC50 = 35 nM). CDK12 ligand-3 degrades CDK12, CDK13 and their regulatory subunit Cyclin K in a concentration dependent manner, and inhibits RNA polymerase II CTD (Ser2) phosphorylation. CDK12 ligand-3 exhibits potent anti proliferative activity against Jurkat cells. CDK12 ligand-3 can be used for research on cancers such as leukemia.

CDH11-IN-1 is a CDH11 inhibitor. CDH11-IN-1 regulates CDH11-mediated biological pathways. CDH11-IN-1 can be used for research on cancer and rheumatoid arthritis.

CDA-IN-5 (Compound M-09) is a Chitin deacetylase inhibitor with a Ki of 27.5 μM against PstCDA. CDA-IN-5 is an antifungal agent. CDA-IN-5 can inhibit infection by Rhizoctonia solani, Pyricularia oryzae, and Botrytis cinerea and exhibits moderate control efficacy against rice sheath blight.

CD38-IN-5 (compound 1) is a CD38 inhibitor that selectively inhibits CD38 hydrolase with an IC50 of 4.0 μM. CD38-IN-5 does not inhibits CD38 cyclase. CD38-IN-5 is highly effective at promoting NK cell-mediated tumor toxicity. CD38-IN-5 increases NADH+ and IFNγ levels in activated PBMCs. CD38-IN-5 can be used for the study of cancer.

CCT368772 (compound 35) is a selective kinesin HSET inhibitor (HSET ADP-Glo IC50 = 0.019 μM). CCT368772 exhibits selectivity over Eg5 (Eg5 ADP-Glo IC50 >200 μM). CCT368772 (compound 152) can be used for the study of hyperproliferative diseases and disorders such as cancer.

CBP/p300 ligand 10 (Compound 3-E) is a CBP/p300 degrader. CBP/p300 ligand 10 also serves as a PROTAC target protein ligand (Ligands for Target Protein for PROTACs) and can be used to synthesize the PROTAC CBP/p300 Degrader-2.

CBLC100 is an anticancer compound that targets FACT, while inhibiting NF-κB and activating p53. CBLC100 induces cytotoxicity through p53-dependent apoptotic and non-apoptotic pathways. CBLC100 is applicable to the research of cancers such as fibrosarcoma.

Cathepsin-IN-5 is a cathepsin inhibitor with IC50 values of 6.2 μM and 81 nM for cathepsin L and cathepsin S. Cathepsin-IN-5 inhibits cancer cells proliferation, induces apoptosis, reduces growth of hepatocellular tumors in mouse models, and modulates expression of genes linked to cell death, cell proliferation, and cellular processes. Cathepsin-IN-5 can be used for the research of hepatocellular carcinoma.

CAST-calpain-2 stabilizer-1 is a blood-brain barrier permeable stabilizer of CAST-calpain-2 interaction. CAST-calpain-2 stabilizer-1 shows no activity against GSK3. CAST-calpain-2 stabilizer-1 can be used in the research of Huntington's disease and tauopathies.

CARM1-IN-6 (Compound iCARM1) dihydrochloride is an effective and selective inhibitor of CARM1 with an IC50 value of 12.3 μM. CARM1-IN-6 dihydrochloride exhibits cell growth inhibitory activity and can be used in cancer research.

Cannabitwinol is a selective thermosensitive TRP modulator and NF-κB inhibitor. Cannabitwinol inhibits TNFα-induced NF-κB-driven transcription and TNFα-induced IL-8 release, and exhibits anti-inflammatory and antioxidant activities. Cannabitwinol shows selectivity for cold-activated TRP channels, activating TRPA1 (EC50 = 3.0 μM) and antagonizing TRPM8 (IC50 = 3.9 μM), but has no significant affinity for heat-activated TRP channels such as TRPV1 and TRPV2. Cannabitwinol can be used in research related to inflammatory skin diseases, cold allodynia, and hyperalgesia.

BWC0977 formic is an antibacterial agent that inhibits bacterial DNA replication via inhibition of DNA gyrase and topoisomerase IV. BWC0977 formic exhibits a minimum inhibitory concentration (MIC90) of 0.03-2 µg/mL against MDR (Multi-Drug Resistant) Gram-negative bacteria.

BW-1003C87 Ethylsulfate is a glutamate release inhibitor. BW-1003C87 Ethylsulfate exhibit neuroprotective effect. BW-1003C87 Ethylsulfate can elevate seizure threshold. BW-1003C87 Ethylsulfate can be used for the research of neurological disease, such as ischemic and seizure.

BSF2 is a anti-Leishmania agent. BSF2 modulates gene expression linked to ubiquitination, chromatin remodeling, and peroxisomal membrane transport pathways in Leishmania braziliensis. BSF2 downregulates TNF, IL-17, NF-κB, and Toll-like receptor pathways in Leishmania-infected macrophages. BSF2 exerts leishmanicidal activity against intracellular Leishmania braziliensis amastigotes. BSF2 can be used for the research of american tegumentary leishmaniasis.

BrP-LPA sodium is a pan-opposite agent for lysophosphatidic acid (LPA). It has antagonistic activity against LPA1 (IC50 = 4520 nM), LPA2 (IC50 = 468 nM), LPA3, and LPA4. BrP-LPA sodium also has partial agonistic activity for LPA5, with its EC50 being 1282 nM. BrP-LPA sodium has ATX inhibitory activity. BrP-LPA sodium effectively inhibits the migration and invasion of breast cancer cells. BrP-LPA sodium achieves tumor regression and anti-angiogenesis in mice breast cancer xenograft model. BrP-LPA sodium can be used for the study of breast cancer.